Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B

Liver International

Volumn 30, Issue 6, 2010, Pages 834-840

  Kim, Hong Joo ^a   Park, Dong Il ^a   Park, Jung Ho ^a   Cho, Yong Kyun ^a   Sohn, Chong Il ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antiviral na ve; Clevudine; Entecavir; Genotypic resistance; Myopathy

Indexed keywords

ALANINE AMINOTRANSFERASE; CLEVUDINE; CREATINE KINASE; ENTECAVIR; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE; HEPATITIS B(E) ANTIGEN; URACIL ARABINOSIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART PALPITATION; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; OPTIC NEURITIS; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; RASH; SIDE EFFECT; SKIN PRURITUS; THYROID DISEASE; VIRUS LOAD; VOMITING; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MUSCLE DISEASE; RETROSPECTIVE STUDY; SOUTH KOREA; TIME; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUSCULAR DISEASES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 77954382306     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02245.x     Document Type: Article

References (19)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997, 337:1733-45.
2. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 national health and nutrition survey in Korea. J Korean Med Sci 2002, 17:457-62.
3. Lok A, McMahon BJ. AASLD chronic hepatitis B: update of recommendations. Hepatology 2004, 39:857-61.
4. Chu CK, Ma T, Shanmuganathan K. Use of 2'-fluoro-5-methyl-β-l-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995, 39:979-81.
5. Yao GQ, Liu SH, Chou E. Inhibition of Epstein-Barr virus replication by a novel l-nucleoside, 2'-fluoro-5-methyl-β-l-arabinofuranosyluracil. Biochem Pharmacol 1996, 51:941-7.
6. Chin R, Shaw T, Torresi J. In vitro susceptibilities of wild-type and drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-β-l-arabinofuranosyluracil. Antimicrob Agents Chemother 2001, 45:2495-501.
7. Yoo BC, Kim JH, Chung YH. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007, 45:1172-8.
8. Kim MH, Kim KA, Lee JS. Efficacy of 48-week clevudine therapy for chronic hepatitis B. Korean J Hepatol 2009, 15:331-7.
9. Ko SY, Kwon SY, Choe WH. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. Antivir Ther 2009, 14:585-90.
10. Seok JI, Lee DK, Lee CH. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49:2080-6.
11. Palumbo E. Entecavir for chronic hepatitis B. Ther Drug Monit 2008, 30:1-4.
12. Lai CL, Rosmawati M, Lao J. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002, 123:1831-8.
13. Sherman M, Yurdayin C. Entecavir for treatment of lamivudine-refractory HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039-49. AI463026 Behold Study Group
14. Lai CL, Shouval D. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-20. AI463027 Behold Study Group
15. Lee CH, Kim SO, Byun KS. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006, 130:1144-52.
16. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 1977, 74:5463-7.
17. Naito H, Hayashi S, Abe K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol 2001, 39:362-4.
18. Lee KS, Byun KS, Chung YH. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNS levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology 2007, 50:296-302.
19. Kim BK, Oh J, Kwon BK. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009, 51:829-34.